IL28B rs12979860 genotype and spontaneous clearance of hepatitis c virus in a multi-ethnic cohort of injection drug users: Evidence for a supra-additive association

Journal of Infectious Diseases

Volumn 204, Issue 12, 2011, Pages 1843-1847

  Shebl, Fatma M ^a   Pfeiffer, Ruth M ^b   Buckett, Dianna ^a,c   Muchmore, Brian ^c   Chen, Sabrina ^d   Dotrang, Myhanh ^e   Prokunina Olsson, Ludmila ^c   Edlin, Brian R ^f,g,h   O'Brien, Thomas R ^a  

^a Infections and Immunoepidemiology Branch   (United States)

^b Biostatistics Branch   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d INFORMATION MANAGEMENT SERVICES INC   (United States)

^e CSC   (United States)

^f Downstate Health Sciences University   (United States)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; COHORT ANALYSIS; DRUG ABUSE; ETHNICITY; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC MODEL; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IL28B GENE; INJECTION DRUG USER; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; STATISTICAL ANALYSIS; VIRAL CLEARANCE;

ADULT; FEMALE; GENE DOSAGE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERLEUKINS; MALE; MIDDLE AGED; MODELS, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; RNA, VIRAL; SUBSTANCE ABUSE, INTRAVENOUS; VIRAL LOAD;

EID: 81055133041     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir647     Document Type: Article

References (14)

1. NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements 2002; 19:1-46.
2. Balagopal A, Thomas DL, Thio CL. IL28B and the control of hepatitis C virus infection. Gastroenterology 2010; 139:1865-76.
3. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801.
4. Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139:120-9.
5. Tillmann HL, Thompson AJ, Patel K, et al. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology 2010; 139:1586-92.
6. Rauch A, Kutalik Z, Descombes P, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138:1338-45.
7. Mangia A, Thompson AJ, Santoro R, et al. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology 2010; 139:821-7827.
8. O'Brien TR, Everhart JE, Morgan TR, et al. An IL28B genotype-based clinical prediction model for treatment of chronic hepatitis C. PLoS One 2011; 6:e20904.
9. Watters JK, Bluthenthal RN, Kral AH. HIV seroprevalence in injection drug users. JAMA 1995; 273:1178.
10. Brown EE, Zhang M, Zarin-Pass R, et al. MBL2 and hepatitis C virus infection among injection drug users. BMC Infect Dis 2008; 8:57.
11. Seal KH, Kral AH, Lorvick J, Gee L, Tsui JI, Edlin BR. Among injection drug users, interest is high, but access low to HCV antiviral therapy. J Gen Intern Med 2005; 20:171.
12. Lewis CM. Genetic association studies: design, analysis and interpretation. Brief Bioinform 2002; 3:146-53.
13. Lindsey JK, Jones B. Choosing among generalized linear models applied to medical data. Stat Med 1998; 17:59-68. (Pubitemid 28020208)
14. Hayes CN, Kobayashi M, Akuta N, et al. HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy. Gut 2011; 60:261-7.